Posted by Michael Wonder on 29 Jan 2020
Health Canada approves new indication for Invokana (canagliflozin) to reduce the risks associated with diabetic kidney disease in patients with type 2 diabetes
28 January 2020 - INVOKANA® is the only diabetes treatment in Canada approved to treat this patient group
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that following a Priority Review, Health Canada has approved Invokana (canagliflozin) as an adjunct to diet, exercise, and standard-of-care therapy, to reduce the risk of end-stage kidney disease, doubling of serum creatinine, and cardiovascular death in adult patients with type 2 diabetes mellitus and diabetic nephropathy (also known as diabetic kidney disease) with albuminuria (>33.9mg/mmol).
The new indication is based on results from the landmark Phase 3 CREDENCE study, the first dedicated renal outcomes study of any sodium-glucose co-transporter 2 inhibitor in patients with type 2 diabetes and diabetic nephropathy.
